There are several looking into long covid. Mostly repurpusing drugs from cronic fatigue and the link. None targeting cd 4, 8 or 49 which are the bio marker targets for inflammation that ATL1102 treats.
So any data aligning any of those bio markers to long covid, and any supporting data that ATL1102 shows some effect is great news for long covid, and also helps build platform drug potential.
As I have said before, inflammation vs treatment of symptoms really is chicken and egg discovery. More recent studies are supportive of deal with inflammation first.
Extremely low MC for the pipeline. I would suggest a few multiples of your 15c would still be under valued.
There are several looking into long covid. Mostly repurpusing...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.6¢ | $148.9K | 1.895M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 48919 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 70000 | 1 |
View Market Depth
| Last trade - 15.59pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
0.000 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.7¢ | 43057 | ||
| Last updated 13.04pm 03/05/2024 ? | |||||
| PER (ASX) Chart |